August 25th 2025
An FDA Form 483 cited unaddressed contamination, pest infestations, and equipment failures at manufacturer’s Bloomington, IN facility, which was acquired in the Catalent buyout.
LogiPharma Europe 2025: How Digitization Drives End-to-End Supply Chain Success
May 21st 2025Ruth Beadle, head, global supply chain, Sanofi, discusses how digital integration, advanced planning, and sustainability goals are transforming end-to-end supply chain operations to improve scale, speed, and environmental impact.
Handling Pharma Supply Chain Disruptions
May 12th 2025In the third part of his Pharma Commerce video interview, Michael Rowe, Two Labs’ senior director of DSCSA/serialization compliance services, shares the challenges that stakeholders are encountering, along with a possible change to the national drug code that could be on the way.
Antares Vision Group, Siempharma Strike Up Pharma Labeling Equipment Collaboration
May 8th 2025The track-and-trace systems provider expands its life sciences portfolio by integrating the high-speed, adaptable ETF-300 precision labeler through a partnership that brings Industry 4.0-ready capabilities, advanced printing tech, and enhanced data security to pharmaceutical packaging.
Will Moving Drug Production to the United States Help or Hurt Patients?
April 25th 2025In the third part of his video interview with Pharma Commerce Editor Nicholas Saraceno, Paul Levesque, CEO of Theratechnologies, explains what the mindset be for companies who are just starting the reshoring process.
Analyzing Tariffs’ Effect on the Biopharmaceutical Supply Chain
April 23rd 2025In the first part of his video interview with Pharma Commerce Editor Nicholas Saraceno, Paul Levesque, CEO of Theratechnologies, outlines how US tariffs on Canadian goods have impacted the company’s operations, particularly in terms of cost and supply chain management in the US market.
The Impact of Pharma Tariffs on Drug Shortages
April 22nd 2025In the final part of his video interview with Pharma Commerce Editor Nicholas Saraceno, Jody Hatcher, CEO of Morris & Dickson and chair of HDA’s board of directors, outlines the implications that potential 25% tariffs on pharmaceuticals could have, as far as manufacturers reshoring their production services are concerned.
The Quest to Deliver Reliability
April 18th 2025In the second part of his video interview with Pharma Commerce Editor Nicholas Saraceno, Jody Hatcher, CEO of Morris & Dickson and chair of HDA’s board of directors, describes his day-to-day workflow at Morris & Dickson, and how it supports the efficiency and reliability of the distributor’s operations.